Citizens Jmp Issues Pessimistic Forecast for Athira Pharma (NASDAQ:LONA) Stock Price

Athira Pharma (NASDAQ:LONA – Get Free Report) had its target price decreased by research analysts at Citizens Jmp from $17.00 to $16.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp‘s price objective would indicate a potential upside of 395.36% from the company’s current price.

A number of other equities research analysts also recently weighed in on LONA. Mizuho dropped their target price on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, August 19th. Wall Street Zen upgraded shares of Athira Pharma to a “hold” rating in a research note on Saturday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, November 4th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Athira Pharma has an average rating of “Moderate Buy” and an average price target of $17.00.

Read Our Latest Analysis on Athira Pharma

Athira Pharma Trading Down 6.9%

Athira Pharma stock opened at $3.23 on Tuesday. Athira Pharma has a 12 month low of $2.21 and a 12 month high of $14.21. The stock’s 50 day moving average is $5.26 and its 200-day moving average is $7.52. The company has a market capitalization of $30.33 million, a price-to-earnings ratio of -0.77 and a beta of 1.90.

Athira Pharma (NASDAQ:LONA – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.27). As a group, equities research analysts predict that Athira Pharma will post -2.67 earnings per share for the current fiscal year.

About Athira Pharma

(Get Free Report)

Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.

Recommended Stories

Analyst Recommendations for Athira Pharma (NASDAQ:LONA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.